ITI Inc (ITCI) was Downgraded by JMP Securities to ” Mkt Perform”. Earlier the firm had a rating of “Mkt Outperform ” on the company shares. JMP Securities advised their investors in a research report released on Sep 29, 2016.
On the company’s financial health, ITI Inc reported $-0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.79. The company had revenue of $.23 million for the quarter, compared to analysts expectations of $.02 million. The company’s revenue was up 283.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.61 EPS.
ITI Inc opened for trading at $40.55 and hit $41.73 on the upside on Tuesday, eventually ending the session at $41.52, with a gain of 1.86% or 0.76 points. The heightened volatility saw the trading volume jump to 4,21,396 shares. Company has a market cap of $1,796 M.
In a different news, on Apr 20, 2016, Rory B Riggs (director) purchased 28,571 shares at $17.50 per share price. According to the SEC, on Dec 15, 2015, Sharon Mates (Chairman, President & CEO) sold 51,500 shares at $54.29 per share price. On Dec 15, 2015, Lawrence J. Hineline (VP of Finance CFO) sold 45,000 shares at $51.56 per share price, according to the Form-4 filing with the securities and exchange commission.
ITI Inc. is a United States-based company. The Company is a subsidiary of Intra-Cellular Therapies Inc.